About IMMUNOTECH-B Company

The Group is a leading cellular immunotherapy biomedical company in China, focusing on the development and commercialization of T-cell immunotherapy for nearly 18 years. EAL - its core product under development - is a multi-target cellular immunotherapy product. It has accumulated a track record of more than ten years in clinical application and has shown therapeutic effects on various cancers. Research related to EAL began in 2006. The Group improved cell culture systems and methods, and developed a proprietary technology platform with independent intellectual property rights for producing EAL cells. The Group chose prevention of recurrence of liver cancer after surgery as a clinical indication for EAL clinical trials. It plans to submit an application to commercialize EAL in the Chinese market after the clinical trial results reach statistical significance. The Group's product pipeline covers major categories of cellular immunotherapy products such as non-genetically-modified and genetically-modified products, as well as multi-target and single-target products. In addition to EAL, the Group's main products under development include 6B11, CAR-T cell series, and TCR-T cell series. The core technical team consists of senior cancer immunologists, who are forward-looking and sensitive to the industry. The R&D team structure covers early R&D, pre-clinical research, clinical research to commercial production and management, enabling product development to advance rapidly. The Group has also established a technical platform for the development of cellular immunotherapy products, and has established an organization and management platform for clinical trials.